Ultomiris Disease Interactions
There are 3 disease interactions with Ultomiris (ravulizumab).
Ravulizumab (applies to Ultomiris) meningitis
Major Potential Hazard, Moderate plausibility. Applicable conditions: CNS Infection
Ravulizumab is contraindicated in patients with unresolved Neisseria meningitidis infection. Life-threatening meningococcal infections have occurred in patients treated with ravulizumab, and the drug has shown to increases patient's susceptibility to serious meningococcal infections (septicemia and/or meningitis). Patients that will receive treatment should be vaccinated for meningococcal disease according to the most current Advisory Committee on Immunization Practices (ACIP) recommendations for patients with complement deficiencies, and revaccinated in accordance with ACIP recommendations considering the duration of ravulizumab therapy. Immunize patients without a history of meningococcal vaccination at least 2 weeks prior to receiving the first dose of ravulizumab. If urgent ravulizumab therapy is indicated in an unvaccinated patient, meningococcal vaccine(s) should be administered as soon as possible with 2 weeks of antibacterial drug prophylaxis. Patients receiving ravulizumab, should be closely monitored for early signs and symptoms of meningococcal infection and if infection is suspected patients need immediate evaluation.
Ravulizumab (applies to Ultomiris) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Ravulizumab blocks terminal complement activation; therefore, patients may have increased susceptibility to encapsulated bacteria infections, especially those caused by Neisseria meningitidis, but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Children treated with ravulizumab are at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenzae type b. Vaccination according to clinical guidelines to prevent these types of infection is recommended. If ravulizumab therapy is administered to patients with active systemic infections, monitor closely for signs and symptoms of worsening infection.
Ravulizumab (applies to Ultomiris) severe renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
The effect of severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2) on ravulizumab pharmacokinetics is unknown.
Switch to professional interaction data
Ultomiris drug interactions
There are 85 drug interactions with Ultomiris (ravulizumab).
More about Ultomiris (ravulizumab)
- Ultomiris consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Enspryng
Enspryng is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...
Zilbrysq
Zilbrysq (zilucoplan) is a C5 inhibitor used to treat generalized myasthenia gravis (gMG) in AChR ...
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Rystiggo
Rystiggo is used to treat generalized myasthenia gravis (gMG) in adults who are acetylcholine ...
Mestinon
Mestinon (pyridostigmine) is used to increase muscle strength in conditions such as myasthenia ...
Vyvgart
Vyvgart is used for myasthenia gravis to improve muscle weakness in adults whose myasthenia gravis ...
Fabhalta
Fabhalta is used to treat paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A ...
Eculizumab
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal ...
Neostigmine
Neostigmine systemic is used for myasthenia gravis, reversal of neuromuscular blockade, reversal of ...
Pyridostigmine
Pyridostigmine systemic is used for dysautonomia, myasthenia gravis, nerve agent pretreatment ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.